Investor FAQs

MediWound Ltd. Is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel products to address unmet needs for severe burns, chronic and other hard-to-heal wounds and connective tissue disorders. The Company’s innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency (EMA) in December 2012 for removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. NexoBrid™ launched in Europe in December 13, 2013, through the Company’s wholly owned German subsidiary.  MediWound operates a cGMP and ISO13485 manufacturing facility for sterile pharmaceutical products and medical devices that meets high quality requirements.
MediWound was founded in 2001.
42 Hayarkon Street, 
Yavne, 8122745, Israel
Meet our management team.
As of 2016, MediWound had 70 employees. 
MediWound is incorporated in the State of Israel.
MediWound’s stock began trading on the NASDAQ Global Market on March 20, 2014. The price of the common shares MediWound sold in its initial public offering was $14.00 per share. Credit Suisse and Jefferies were the joint lead book-running managers for the offering. BMO Capital Markets also acted as a book-running manager. Oppenheimer & Co. acted as co-manager. 
A final prospectus relating to these securities may be obtained by going to our SEC Filings page or by contacting: 
Credit Suisse Securities (USA) LLC 
Attention: Prospectus Department, 
One Madison Avenue 
New York, New York 10010 
(800) 221-1037
Jefferies LLC 
Equity Syndicate Prospectus Department, 
520 Madison Avenue, 12th Floor, 
New York, NY, 10022 
MediWound’s common stock is traded on the NASDAQ Global Market under the symbol “MDWD.”
All events will be reported on this site. Please see the event page for more information. You can also sign up for email alerts.
If you would like to purchase shares in MediWound, please contact your broker.
We do not offer a direct stock purchase or dividend reinvestment program.
MediWound does not anticipate paying any cash dividends in the foreseeable future.
Our fiscal year follows the calendar year, with the last day of our fiscal year occurring on December 31. The Company’s quarterly periods conclude on March 31, June 30, September 30, and December 31.
The transfer agent and registrar for the company's common stock is
American Stock Transfer & Trust Company
6201 15th Avenue
Brooklyn, New York 11219
T: (800) 937-5449 (U.S.) or (718) 921-8200 (International)
You can go to the official SEC site or you can follow this link to our page.
Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, located in Israel.
Jeremy Feffer
Managing Director
LifeSci Advisors